Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.
about
Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vectorVaccines in development against West Nile virusExperimental infection of rhesus macaques and common marmosets with a European strain of West Nile virusA Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsPlant-made vaccines against West Nile virus are potent, safe, and economically feasibleAssurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.Current trends in West Nile virus vaccine development.Experimental West Nile Virus Infection in Rabbits: An Alternative Model for Studying Induction of Disease and Virus Control.Novel vaccine strategies against emerging viruses.A review of vaccine approaches for West Nile virus.The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.A review of the epidemiological and clinical aspects of West Nile virus.Application of West Nile virus diagnostic techniques.Current developments in understanding of West Nile virus central nervous system disease.Lineage-Specific Real-Time RT-PCR for Yellow Fever Virus Outbreak Surveillance, Brazil.Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein.Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.The Immune Responses of the Animal Hosts of West Nile Virus: A Comparison of Insects, Birds, and Mammals.A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen
P2860
Q26247032-90F09EF3-D599-450F-93F9-F6E221B101BCQ26999702-7CF4D841-06FB-498D-B763-9AECEDCCFA38Q27304916-E12986A8-1C65-4E8D-B626-73DD794CDCD3Q27321020-E23AAD94-89DC-4EBE-8D0B-18299C5CC997Q28082778-57E25895-4577-474B-9C3F-EA51928298F9Q33909344-FA7F377B-39EF-4C5F-B9EB-99D3137967D4Q34788758-FB49ABA9-5928-4DFD-841D-90C024C8A3CEQ36096374-4CBB80F7-F79E-4104-B719-4DA3A22CA5C7Q36816140-923D8BB6-BF93-4726-87F3-ECD484A9BB15Q37236968-5253654D-A6AA-499E-8AA5-9A886FBFDEE1Q37324444-E5046292-F111-4A2D-9B6B-DA179708CF82Q37666763-91814796-CE75-46A1-A4E3-CD60C5DDD993Q37708659-245AA554-977D-4CFC-9F90-C29D982966BBQ38131535-31D5D04E-0895-41E9-98DB-4F3A9A4FC128Q38203769-E003D985-5E6F-48D3-A6DA-282701DDE6E0Q41928914-D0873C7F-9BAC-4D1C-AA15-97F5E17A418FQ42235222-93E8AD12-67F8-4627-AA8B-1CD8759E80B3Q43047253-6C86CB60-8756-4FFD-A187-7DB9A3501343Q52880885-8150E77C-E7B0-4D08-930E-72C5C077B08BQ57299898-4AFC99FB-9A99-4DBF-9AF4-860102154F89
P2860
Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase II, dose ranging study o ...... lthy adults ≥ 50 years of age.
@en
type
label
Phase II, dose ranging study o ...... lthy adults ≥ 50 years of age.
@en
prefLabel
Phase II, dose ranging study o ...... lthy adults ≥ 50 years of age.
@en
P2093
P1433
P1476
Phase II, dose ranging study o ...... lthy adults ≥ 50 years of age.
@en
P2093
Aileen Buldo
Dorothy Coleman
George Risi
Joan Bevilacqua
P304
P356
10.1016/J.VACCINE.2012.08.063
P407
P577
2012-09-07T00:00:00Z